SBE22 Antibody

What is SBE22 antibody and what is its primary target?

SBE22 antibody is a research tool developed to target the Sterol Regulatory Element-Binding Protein 2 (SREBP2), a critical transcription factor that regulates cholesterol biosynthesis. SREBP2 exists in two forms: a precursor embedded in the endoplasmic reticulum membrane and a processed transcription factor form that translocates to the nucleus when sterol concentrations are low. The processed form binds to sterol regulatory element 1 (SRE-1) with the sequence 5'-ATCACCCCAC-3' and also demonstrates dual sequence specificity by binding to an E-box motif (5'-ATCACGTGA-3') . This antibody enables researchers to study cholesterol homeostasis mechanisms and related metabolic pathways.

What experimental applications is SBE22 antibody validated for?

SBE22 antibody has been validated for multiple experimental applications including:

• Western blot (WB) analysis for detecting SREBP2 expression levels

• Immunocytochemistry/immunofluorescence (ICC/IF) for visualizing SREBP2 cellular localization

• Studying transcriptional regulation of cholesterol biosynthesis genes

• Investigating SREBP2 processing mechanisms from precursor to active form

• Examining sterol-dependent regulatory pathways

The antibody shows confirmed reactivity in human, mouse, and rat samples, making it suitable for comparative studies across these species .

How can researchers distinguish between precursor and processed forms of SREBP2?

Distinguishing between the precursor (~125 kDa) and processed forms (~68 kDa) of SREBP2 requires careful experimental design:

• Use 8-10% SDS-PAGE gels to effectively separate these forms based on molecular weight

• Perform subcellular fractionation to isolate ER membrane (precursor) and nuclear (processed) fractions

• Employ sterol depletion conditions as a positive control to increase processed form abundance

• Include appropriate molecular weight markers spanning 50-150 kDa

• Consider using phospho-specific antibodies if studying regulatory phosphorylation events

This discrimination is crucial when investigating SREBP2 activation mechanisms in response to cellular sterol levels.

What are the optimal conditions for using SBE22 antibody in Western blot analysis?

For optimal Western blot results with SBE22 antibody, researchers should consider the following protocol adaptations:

• Sample preparation:

  • Include protease inhibitors to prevent SREBP2 degradation

  • For nuclear SREBP2 detection, optimize nuclear extraction protocols

  • Standardize sample collection conditions regarding cell confluence and sterol status

• Electrophoresis and transfer:

  • Use 8-10% acrylamide gels to resolve both precursor and processed forms

  • Employ wet transfer with reduced methanol concentration for efficient transfer of larger precursor form

• Antibody incubation:

  • Block membranes with 5% BSA in TBST (preferable to milk for phosphoprotein detection)

  • Use overnight primary antibody incubation at 4°C at dilutions between 1:500-1:2000

  • Include positive controls from cells with known SREBP2 expression

These optimizations help ensure consistent and specific detection of SREBP2 in experimental samples.

How can researchers evaluate antibody specificity for SREBP2 research?

To ensure SBE22 antibody specificity, implement these validation strategies:

• Genetic validation:

  • Use SREBP2 knockout/knockdown samples as negative controls

  • Compare signal patterns between control and SREBP2-deficient samples

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide

  • Observe signal reduction as evidence of specificity

• Cross-reactivity assessment:

  • Test against related family members (especially SREBP1)

  • Use cells with differential expression of related proteins

• Multiple detection methods:

  • Confirm findings using orthogonal techniques like mass spectrometry

  • Employ antibodies targeting different SREBP2 epitopes

This comprehensive validation approach ensures experimental findings accurately reflect SREBP2 biology rather than artifacts of antibody cross-reactivity .

What considerations are important when investigating transcription factor dynamics with SBE22 antibody?

When studying SREBP2 dynamics with SBE22 antibody, researchers should consider:

• Regulatory context:

  • Standardize cellular cholesterol status, as low sterol concentrations promote SREBP2 processing

  • Control for serum conditions that may affect SREBP2 processing

  • Document time course of cholesterol depletion/repletion

• Subcellular localization:

  • Use complementary markers for ER (e.g., calnexin) and nucleus (e.g., DAPI)

  • Perform parallel biochemical fractionation to confirm imaging results

  • Consider live-cell imaging to capture dynamic translocation events

• Protein-protein interactions:

  • Investigate interactions with processing machinery (SCAP, Insigs)

  • Examine co-regulatory factors at target gene promoters

  • Assess post-translational modifications affecting activity

• Functional readouts:

  • Measure transcriptional activation of SREBP2 target genes

  • Assess cholesterol biosynthesis rates in parallel

  • Correlate protein detection with functional outcomes

This multi-faceted approach enables comprehensive understanding of SREBP2 regulatory mechanisms.

How can SBE22 antibody be used to investigate protein-protein interactions in sterol-sensing pathways?

SBE22 antibody can facilitate protein-protein interaction studies through several approaches:

• Co-immunoprecipitation (Co-IP):

  • Use SBE22 antibody to pull down SREBP2 complexes

  • Identify interacting partners through Western blot or mass spectrometry

  • Compare interaction profiles under different sterol conditions

• Proximity ligation assay (PLA):

  • Combine SBE22 with antibodies against suspected interaction partners

  • Visualize interactions as fluorescent spots by microscopy

  • Quantify interaction frequency under various experimental conditions

• Chromatin immunoprecipitation (ChIP):

  • Use SBE22 antibody to isolate SREBP2-bound chromatin

  • Identify genomic binding sites through sequencing (ChIP-seq)

  • Assess co-occupancy with other transcription factors or cofactors

• Automated high-content imaging:

  • Track SREBP2 localization relative to interaction partners

  • Perform siRNA screens to identify novel regulatory proteins

  • Quantify effects of potential therapeutic compounds

These approaches provide mechanistic insights into how SREBP2 functions within larger regulatory networks controlling lipid metabolism.

What are the challenges of working with antibodies in complex biological fluids and how can they be addressed?

When working with antibodies in complex biological fluids, researchers face several challenges:

• Nonideal interactions:

  • Antibodies experience global nonideality in serum due to interactions with various components

  • Second virial coefficient (B₂,app) can be measured to quantify these nonideal behaviors

  • Entropic and enthalpic effects from the bulk environment affect antibody function

• Methodological solutions:

  • Use fluorescence correlation spectroscopy (FCS) to assess antibody behavior in complex media

  • Employ 50 μL sample aliquots on cover glass for reproducible measurements

  • Calibrate instruments with standardized fluorescent markers (e.g., 10 nM A488)

• Experimental controls:

  • Compare antibody performance in buffer versus biological fluid

  • Include concentration gradients to assess concentration-dependent effects

  • Control for pH and temperature, as these parameters influence interactions

• Data interpretation:

  • Consider how bulk fluid properties might affect apparent binding constants

  • Incorporate nonideality assessments into therapeutic antibody development

  • Validate findings from simplified systems in more complex environments

Understanding these principles is particularly important when translating in vitro findings to in vivo applications or therapeutic development .

How does antibody selection methodology impact research applications?

The method used to select and develop antibodies significantly impacts their research utility:

These methodological considerations directly impact antibody performance characteristics and experimental reliability.

How do antibodies targeting different protein domains provide complementary research insights?

Antibodies targeting different domains of the same protein provide distinct and complementary research value:

This domain-specific approach allows researchers to build comprehensive understanding of protein function from complementary perspectives rather than relying on a single antibody.

What insights from viral antibody research can be applied to transcription factor antibody development?

Research on viral neutralizing antibodies offers valuable insights applicable to transcription factor antibody development:

• Epitope targeting strategies:

  • Target conserved, functionally critical domains (like the fusion peptide in viral proteins)

  • Focus on regions with structural constraints to minimize escape mutations

  • This approach can be applied to target conserved DNA-binding domains in transcription factors

• Functional screening approaches:

  • Viral antibodies are assessed for neutralization via cytopathic effect assays

  • Similar function-first screening can identify transcription factor antibodies that disrupt DNA binding or protein-protein interactions

  • Automated image analysis enables quantitative functional evaluation

• Effector function considerations:

  • Some antibodies mediate effects through ADCC rather than direct neutralization

  • Similarly, transcription factor antibodies may disrupt function through steric hindrance or allosteric effects

  • Multiple functional readouts should be assessed beyond simple binding

• Combinatorial approaches:

  • Antibody combinations can provide synergistic effects against viral targets

  • Similar combinations targeting different transcription factor epitopes may offer enhanced inhibition

  • This strategy overcomes limitations of single-epitope targeting

These translational insights enhance antibody tool development across research domains.

How can researchers assess potential off-target effects of antibodies in experimental systems?

Systematic assessment of antibody off-target effects should include:

• Cross-reactivity profiling:

  • Test against structurally related family members (e.g., SREBP1 for SREBP2 antibodies)

  • Perform immunoprecipitation followed by mass spectrometry to identify all bound proteins

  • Use tissue/cells from knockout organisms as definitive negative controls

• Computational prediction:

  • Analyze epitope sequence for homology to other proteins

  • Predict potential cross-reactive targets based on structural similarity

  • Prioritize validation experiments based on computational risk assessment

• Functional validation:

  • Compare phenotypes from antibody treatment versus genetic manipulation

  • Test multiple antibodies targeting different epitopes on the same protein

  • Assess dose-dependent effects to distinguish specific from non-specific interactions

• Control experiments:

  • Include isotype-matched control antibodies

  • Use peptide competition to confirm specificity

  • Implement CRISPR knockout controls for definitive validation

This comprehensive approach minimizes experimental artifacts and misinterpretation of results due to antibody off-target effects.

What are common challenges when using SBE22 antibody in immunofluorescence, and how can they be resolved?

When using SBE22 antibody for immunofluorescence, researchers may encounter several challenges:

• Nuclear signal detection issues:

  • Problem: Weak or absent nuclear signal despite SREBP2 activation

  • Solution: Enhance nuclear permeabilization with 0.3% Triton X-100; use sterol depletion to increase nuclear SREBP2; extend primary antibody incubation to overnight at 4°C

• Dual localization visualization:

  • Problem: Difficulty visualizing both ER and nuclear pools simultaneously

  • Solution: Use confocal microscopy with z-stacking; employ subcellular markers; optimize fixation to preserve both pools (4% paraformaldehyde for 15 minutes)

• Background fluorescence:

  • Problem: High non-specific background masking specific signal

  • Solution: Increase blocking time (2 hours at room temperature); use 5% BSA with 0.1% Tween-20; include secondary-only controls; titrate antibody concentration

• Signal variability between cells:

  • Problem: Heterogeneous staining pattern across cell population

  • Solution: Standardize cell culture conditions; synchronize cells; control for cell cycle stage; quantify signal across larger cell populations

• Specificity confirmation:

  • Problem: Uncertainty whether signal represents SREBP2 specifically

  • Solution: Include SREBP2 knockdown controls; perform peptide competition; use orthogonal detection methods

These optimizations substantially improve detection specificity and experimental reliability.

How should researchers approach antibody validation for novel experimental systems?

When validating SBE22 antibody for new experimental systems, follow this systematic approach:

• Initial assessment:

  • Verify species cross-reactivity based on epitope sequence conservation

  • Start with applications the antibody is already validated for (e.g., Western blot)

  • Test multiple antibody concentrations to establish optimal working range

• Stepwise validation protocol:

  • Begin with positive control samples (cells/tissues known to express SREBP2)

  • Include negative controls (knockout/knockdown samples when available)

  • Test under conditions that modulate SREBP2 (sterol depletion/repletion)

• Application-specific considerations:

  • For immunoprecipitation: Optimize lysis conditions to preserve epitope accessibility

  • For flow cytometry: Develop appropriate fixation/permeabilization for intracellular detection

  • For ChIP applications: Test fixation time and sonication conditions

• Quantitative assessment:

  • Measure signal-to-noise ratios across conditions

  • Establish reproducibility through independent replicates

  • Document lot-to-lot variation if using antibody long-term

This structured validation approach ensures reliable antibody performance in new experimental systems.